5NHJ

Human Erk2 with an Erk1/2 inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.12 Å
  • R-Value Free: 0.207 
  • R-Value Work: 0.201 
  • R-Value Observed: 0.202 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.

Ward, R.A.Bethel, P.Cook, C.Davies, E.Debreczeni, J.E.Fairley, G.Feron, L.Flemington, V.Graham, M.A.Greenwood, R.Griffin, N.Hanson, L.Hopcroft, P.Howard, T.D.Hudson, J.James, M.Jones, C.D.Jones, C.R.Lamont, S.Lewis, R.Lindsay, N.Roberts, K.Simpson, I.St-Gallay, S.Swallow, S.Tang, J.Tonge, M.Wang, Z.Zhai, B.

(2017) J Med Chem 60: 3438-3450

  • DOI: 10.1021/acs.jmedchem.7b00267
  • Primary Citation of Related Structures:  
    5NHH, 5NHJ, 5NHL, 5NHF, 5NGU, 5NHP, 5NHO, 5NHV

  • PubMed Abstract: 
  • There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications. The inhibition of ERK1/2 is of significa ...

    There are a number of small-molecule inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clinical development for oncology across a range of disease indications. The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition in preclinical models. This article reports on our recent work to identify novel, potent, and selective reversible ERK1/2 inhibitors from a low-molecular-weight, modestly active, and highly promiscuous chemical start point, compound 4. To guide and inform the evolution of this series, inhibitor binding mode information from X-ray crystal structures was critical in the rapid exploration of this template to compound 35, which was active when tested in in vivo antitumor efficacy experiments.


    Organizational Affiliation

    Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA, Beijing, 100176, P.R. China.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 1A381Homo sapiensMutation(s): 0 
Gene Names: MAPK1ERK2PRKM1PRKM2
EC: 2.7.11.24
Find proteins for P28482 (Homo sapiens)
Explore P28482 
Go to UniProtKB:  P28482
NIH Common Fund Data Resources
PHAROS  P28482
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
8XE
Query on 8XE

Download Ideal Coordinates CCD File 
A
5-(2-methoxyethyl)-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-6,7-dihydro-1~{H}-pyrrolo[3,2-c]pyridin-4-one
C18 H21 N7 O2
HKLUILZKCLFHGM-UHFFFAOYSA-N
 Ligand Interaction
SO4
Query on SO4

Download Ideal Coordinates CCD File 
A
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
8XEIC50:  0.30000001192092896   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.12 Å
  • R-Value Free: 0.207 
  • R-Value Work: 0.201 
  • R-Value Observed: 0.202 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 49.025α = 90
b = 71.158β = 112.03
c = 61.398γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
xia2data reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Revision History 

  • Version 1.0: 2017-04-19
    Type: Initial release
  • Version 1.1: 2017-05-10
    Changes: Database references